Personalis, Inc. $PSNL Stock Position Lessened by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. decreased its stake in shares of Personalis, Inc. (NASDAQ:PSNL) by 6.6% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 484,270 shares of the company’s stock after selling 34,171 shares during the period. Sumitomo Mitsui Trust Group Inc.’s holdings in Personalis were worth $3,085,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Caitong International Asset Management Co. Ltd grew its holdings in Personalis by 76.1% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,423 shares of the company’s stock worth $27,000 after acquiring an additional 1,479 shares during the period. Deutsche Bank AG raised its holdings in shares of Personalis by 4.5% during the fourth quarter. Deutsche Bank AG now owns 38,827 shares of the company’s stock valued at $309,000 after acquiring an additional 1,655 shares during the period. Royal Bank of Canada raised its stake in Personalis by 3.2% during the 1st quarter. Royal Bank of Canada now owns 78,341 shares of the company’s stock valued at $275,000 after purchasing an additional 2,395 shares during the period. Howland Capital Management LLC raised its position in Personalis by 0.9% during the second quarter. Howland Capital Management LLC now owns 285,308 shares of the company’s stock valued at $1,872,000 after buying an additional 2,500 shares during the period. Finally, Intech Investment Management LLC increased its holdings in shares of Personalis by 23.4% in the 4th quarter. Intech Investment Management LLC now owns 20,342 shares of the company’s stock valued at $162,000 after purchasing an additional 3,851 shares during the period. 61.91% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, CEO Christopher M. Hall sold 100,000 shares of the stock in a transaction that occurred on Friday, June 26th. The shares were sold at an average price of $13.15, for a total transaction of $1,315,000.00. Following the sale, the chief executive officer directly owned 235,986 shares of the company’s stock, valued at $3,103,215.90. This represents a 29.76% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Aaron Tachibana sold 51,251 shares of the stock in a transaction on Friday, June 26th. The shares were sold at an average price of $13.18, for a total value of $675,488.18. Following the completion of the transaction, the chief financial officer owned 198,833 shares in the company, valued at $2,620,618.94. The trade was a 20.49% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 435,032 shares of company stock worth $5,599,929 over the last quarter. 4.20% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on PSNL shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Personalis in a research note on Tuesday, April 21st. Wall Street Zen cut shares of Personalis from a “hold” rating to a “sell” rating in a research note on Saturday, June 13th. BTIG Research cut their price objective on Personalis from $13.00 to $11.00 and set a “buy” rating for the company in a research report on Monday, May 11th. Morgan Stanley upped their target price on shares of Personalis from $9.00 to $13.00 and gave the company an “equal weight” rating in a research note on Thursday, July 9th. Finally, TD Cowen reiterated a “buy” rating on shares of Personalis in a research report on Wednesday. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $11.67.

Personalis Stock Up 5.1%

Shares of PSNL stock opened at $15.79 on Thursday. The company has a market capitalization of $1.65 billion, a P/E ratio of -15.48 and a beta of 2.24. Personalis, Inc. has a 12-month low of $3.84 and a 12-month high of $16.15. The firm has a 50-day moving average price of $10.56 and a 200 day moving average price of $8.80.

Personalis (NASDAQ:PSNL) last released its quarterly earnings results on Thursday, May 7th. The company reported ($0.29) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.06). The business had revenue of $15.47 million for the quarter, compared to the consensus estimate of $14.48 million. Personalis had a negative return on equity of 43.52% and a negative net margin of 148.11%. As a group, research analysts expect that Personalis, Inc. will post -1.07 earnings per share for the current year.

Personalis Profile

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.